Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336883 | 0.94 | KDM4E (0.65) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL2331568 | 0.92 | KDM4E (0.63) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL13943667 | 0.92 | SIGMAR1 (0.64) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL16226310 | 0.90 | KDM4E (0.54) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL24163317 | 0.89 | RECQL (0.69) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL16226512 | 0.87 | ALDH1A1 (0.56) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL4797625 | 0.85 | SIGMAR1 (0.69) | TSHRRECQLSMN1; SMN2SIGMAR1TRPV6 | |
| SCHEMBL5050001 | 0.84 | L3MBTL3 (0.59) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL28851994 | 0.84 | KDM4E (0.55) | KMT2AKDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL5052507 | 0.84 | L3MBTL3 (0.59) | KMT2AKDM4EMEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | KMT2A 2536/4885KDM4E 4836/4885MEN1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.